Continued improvement in survival in multiple myeloma (MM) including high-risk patients.

person Bharat Nandakumar Division of Hematology,Mayo Clinic, Rochester, MN info_outline Bharat Nandakumar, Moritz Binder, Angela Dispenzieri, Prashant Kapoor, Francis Buadi, Morie A. Gertz, Martha Lacy, David Dingli, Lisa Hwa, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Rahma M. Warsame, Ronald S. Go, Miriam A. Hobbs, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar, Suzanne R. Hayman

Authors person Bharat Nandakumar Division of Hematology,Mayo Clinic, Rochester, MN info_outline Bharat Nandakumar, Moritz Binder, Angela Dispenzieri, Prashant Kapoor, Francis Buadi, Morie A. Gertz, Martha Lacy, David Dingli, Lisa Hwa, Nelson Leung, Wilson I. Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Rahma M. Warsame, Ronald S. Go, Miriam A. Hobbs, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar, Suzanne R. Hayman Organizations Division of Hematology,Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester, MN, Division of Hematology, Mayo Clinic, Rochester, MN, Mayo Clinic, Division of Hematology, Rochester, MN Abstract Disclosures Research Funding U.S. National Institutes of Health Background: Treatment of MM has evolved significantly over the past decade, with increasing use of multi-drug combinations for initial therapy. In addition, supportive care approaches have also improved. We examined how these improvements have translated to survival outcomes in patients with newly diagnosed MM. Methods: Patients (n=3449) with a diagnosis of MM made between 2004 and 2017 and seen at Mayo Clinic within six months of the diagnosis, were included in this analysis. Patients were divided into three groups based on the year of diagnosis; group 1- 2004-07 (n=831), group 2-2008-12 (n=1161), and group 3-2013-17 (n=1457). Survival of the groups were estimated using Kaplan-Meier method, and compared using log rank test. Results: The median age was 64 years (22 to 96); 60% were male and 40% were female. 14% were >75 years, 33% were aged 65-75 and 53% were <65 years. The median overall survival for the whole cohort was 5.7 years (95%CI; 5.4, 6.3). The median OS for the groups 1, 2 and 3 were 3.9, 6.3 and NR, respectively; p<0.001. The 4-year survival estimates were 50%, 62%, and 75%, respectively. We then explored the improvements in patient subgroups. While all patients experienced improvements in OS over time, improvement in group 3 was most prominent for those >75 years. In patients <65 years, the 4-yr OS for groups 1, 2 and 3 were 57, 71, and 79% respectively. In patients 65-75 years of age, the 4-yr OS for groups 1, 2 and 3 were 48, 60, and 75% respectively. In patients >75 years, the 4-yr OS for groups 1, 2 and 3 were 24, 35, and 56% respectively. While patients with high-risk disease did not see as much benefit in the earlier period, substantial progress was seen in the last group. The 3-yr OS for patients with high-risk cytogenetics were 52, 55, and 73% for groups 1, 2 and 3 compared to 67, 75, and 85% for standard-risk cytogenetics respectively. 2067 patients were staged according to the International Staging System and the median OS for stages 1, 2 and 3 were 6.5, 4.6 and 2.4 in group 1; 9.2, 6.6 and 3.5 in group 2 and NR for any of the stages in group 3. Conclusions: The results confirm continued improvement in survival of newly diagnosed multiple myeloma patients, including elderly and high-risk MM.